Investigating the Therapeutic Effects of Temozolomide Through Histone Methylation Analysis

<p><strong>Abstract</strong></p>\n<p>While extensive research has focused on the methylation of DNA by the anticancer drug temozolomide (TMZ), there remains a gap in our understanding of its potential to methylate proteins. In a previous study, we demonstrated that TMZ can methylate histone proteins in vitro using purified recombinant protein. Our current investigation aims to explore the therapeutic benefits of TMZ through protein methylation in breast cancer cells and understand how TMZ impacts protein levels via this mechanism. Specifically, we are interested in histone proteins due to their role in DNA binding and gene regulation. To assess methylation levels, we employed a biochemical method, treating cancer cells with varying concentrations of TMZ. Our results suggest that TMZ may indeed influence histone protein levels in cancer cells although further experiments are necessary to validate our observation. This research direction is intriguing because it could reveal a novel aspect of TMZ’s antitumor activity beyond its known interactions at the DNA level. By focusing on protein methylation, we expand our understanding of TMZ’s effects on cancer cells. This work could potentially uncover new insights into TMZ's efficacy and possibly identify new therapeutic targets or strategies for cancer treatment.</p>